Financing - March 5, 2020
Lundbeck receives grant from The Michael J. Fox Foundation
Lundbeck will begin research on a novel method for earlier and more precise diagnosis of Parkinson’s disease, the likes of which do not currently exist. By diagnosing Parkinson’s disease as early as possible, patients can benefit from a greater choice in treatment options. This research is funded by The Michael J. Fox Foundation for Parkinson’s […]
Pharma Business - February 25, 2020
FDA approves Lundbeck’s intravenous preventive treatment for migraine
Lundbeck has announced that Vyepti (eptinezumab-jjmr) has been approved by the U.S. Food and Drug Administration (FDA) for the preventive treatment of migraine in adults and will be available in April 2020. Vyepti is the first FDA-approved intravenous (IV) treatment for migraine prevention. “With the approval of Vyepti, I am pleased that we are now able […]
Global report - January 22, 2020
Lundbeck, AstraZeneca & Novo Nordisk on ‘A List’ for climate change
A new global ranking puts Lundbeck, AstraZeneca and Novo Nordisk in the top 2% of more than 8,400 companies evaluated for their actions against climate change. The companies’ efforts to reduce CO2-emissions and energy consumption has been recognized by the independent interest group Carbon Disclosure Project (CDP), which sets the global standard for actions against […]
New Market - September 23, 2019
Lundbeck and Takeda announce approval of Trintellix in Japan
The two companies jointly announced today that the MHLW of Japan approved Trintellix (vortioxetine) for the treatment of depression and depressed state. The NDA filing submitted to the MHLW in September 2018 included data from a phase III trial, which demonstrated statistically significant improvement in overall symptoms of depression in adults as compared to placebo. […]
Acquisition - September 16, 2019
Lundbeck to acquire Alder BioPharmaceuticals
Lundbeck and Alder BioPharmaceuticals have announced a definitive agreement for Lundbeck to acquire Alder in a transaction valued at up to USD 1.95 billion net of cash. Alder is a clinical-stage biopharmaceutical company committed to transforming migraine treatment through the discovery, development and commercialization of novel therapeutic antibodies. Through this acquisition, Lundbeck will continue to expand […]
Acquisition - May 7, 2019
Lundbeck to acquire Abide Therapeutics
Lundbeck and Abide Therapeutics have announced signing of a definitive agreement in which Lundbeck LLC has agreed to acquire Abide. Under the terms of the agreement, Lundbeck may pay USD 250 million (approximately DKK 1.65 billion) upfront with a commitment to pay future development and sales milestones to the group of current owners of up […]
